Heron Therapeutics, Inc.
General ticker "HRTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $264.9M (TTM average)
Heron Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -27.0%.
Estimated limits based on current volatility of 4.0%: low 1.17$, high 1.26$
Factors to consider:
- Total employees count: 122 (-3.2%) as of 2024
- Top business risk factors: Dependence on product success, Market acceptance, Market competition, Reimbursement risks, Regulatory and compliance
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.94$, 2.51$]
- 2025-12-31 to 2026-12-31 estimated range: [0.87$, 2.32$]
Financial Metrics affecting the HRTX estimates:
- Positive: with PPE of -17.3 at the end of fiscal year the price was low
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of 7.86 > -0.66
- Negative: Operating cash flow per share per price, % of -9.47 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: Interest expense per share per price, % of 2.53 <= 3.41
Short-term HRTX quotes
Long-term HRTX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $107.67MM | $127.04MM | $144.28MM |
| Operating Expenses | $282.33MM | $237.66MM | $155.81MM |
| Operating Income | $-174.66MM | $-110.61MM | $-11.53MM |
| Non-Operating Income | $-7.37MM | $0.06MM | $-2.05MM |
| Interest Expense | $2.47MM | $3.87MM | $6.03MM |
| R&D Expense | $82.70MM | $39.13MM | $16.68MM |
| Income(Loss) | $-182.02MM | $-110.56MM | $-13.58MM |
| Profit(Loss)* | $-182.02MM | $-110.56MM | $-13.58MM |
| Stockholders Equity | $13.57MM | $-33.97MM | $-33.65MM |
| Inventory | $54.57MM | $42.11MM | $53.16MM |
| Assets | $250.95MM | $222.51MM | $233.15MM |
| Operating Cash Flow | $-146.91MM | $-58.79MM | $-22.53MM |
| Capital expenditure | $1.82MM | $1.54MM | $1.71MM |
| Investing Cash Flow | $-3.32MM | $18.00MM | $18.71MM |
| Financing Cash Flow | $75.06MM | $54.11MM | $0.94MM |
| Earnings Per Share** | $-1.67 | $-0.80 | $-0.09 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.